Krajina-Andricević Mirna, Zibar Lada, Juras Karin, Goll-Barić Sanda, Barbić Jerko
Vinkovci General Hospital, Department of Internal Medicine, Vinkovci, Croatia.
Coll Antropol. 2011 Jun;35(2):537-42.
Angiotensin converting enzyme (ACE) inhibitors provide well known cardiorenal-protective benefits added to antihypertensive effects in chronic renal disease. These agents are underused in management of patients receiving hemodialysis (HD) because of common concern of hyperkalemia. However, few studies have investigated effect of renin angiotensin aldosterone system (RAAS) blockade on serum potassium in hemodialysis patients. We assessed the safety of ramipril in patients on maintenance HD. We enrolled 28 adult end stage renal disease (ESRD) patients treated by maintenance HD and prescribed them ramipril in doses of 1.25 to 5 mg per day. They underwent serum potassium concentration measurements before ramipril introduction and in 1 to 3 months afterwards. No significant increase in kalemia was found. Results of our study encourage the use of ACE inhibitors in chronically hemodialyzed patients, but close potassium monitoring is mandatory.
血管紧张素转换酶（ACE）抑制剂在慢性肾病中除具有降压作用外，还具有众所周知的心脏和肾脏保护益处。由于普遍担心高钾血症，这些药物在接受血液透析（HD）的患者管理中未得到充分使用。然而，很少有研究调查肾素血管紧张素醛固酮系统（RAAS）阻断对血液透析患者血清钾的影响。我们评估了雷米普利在维持性血液透析患者中的安全性。我们招募了28例接受维持性血液透析治疗的成年终末期肾病（ESRD）患者，并给他们开具了每日1.25至5毫克剂量的雷米普利。在引入雷米普利之前和之后1至3个月，他们接受了血清钾浓度测量。未发现血钾有显著升高。我们的研究结果鼓励在长期血液透析患者中使用ACE抑制剂，但必须密切监测血钾。
